NoticesDocument number 2026-20705New
Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With Thrombocytopenia Syndrome Virus Antigen and Use Thereof
The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to Korea National Institute of Health, located in Cheongju-si, Chungcheongbuk-do, South Korea to practice the invention embodied in the patent application listed in the Supplementary Information section of this notice.
From Federal Register — all agencies (federalregister.gov). First seen Oct 10, 2026.
Details
- Published
- Oct 9, 2026Find in source ↗
- Agency
- Health and Human Services Department; National Institutes of HealthFind in source ↗
- Comments close
- Oct 26, 2026Find in source ↗
- Action
- Notice.Find in source ↗
- Dates statement
- Only written comments and/or applications for a license which are received by the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases on or before October 26, 2026 will be considered.Find in source ↗
- Citation
- 91 FR 64672Find in source ↗
- Official PDF
- govinfo.gov
History
No changes since RuleWatch first read this rule on Oct 10, 2026.
Sign in to keep notes on this rule, private or shared with your team.